{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["5(3)"],"submitter":["Ravi N"],"pubmed_abstract":["<h4>Aim</h4>There is limited data on prognostic value of baseline plasma cell free DNA (cfDNA) in advanced squamous non-small cell lung cancer (sq-NSCLC). This prospective observational study aimed to assess change in plasma cfDNA levels in locally-advanced/metastatic sq-NSCLC with chemotherapy and its correlation with symptom-scores and radiological-responses.<h4>Methods</h4>Chemotherapy-naive patients with stages-IIIB/IIIC/IV sq-NSCLC (<i>n</i> = 59), smokers with chronic obstructive pulmonary disease [COPD, COPD-controls (CC); <i>n</i> = 27] and healthy-controls (<i>n</i> = 25) were enrolled. Respiratory symptom burden (RSB) and total symptom burden (TSB) were calculated from mean visual-analog-scores (VAS) of dyspnoea, cough, chest pain, hemoptysis RSB, anorexia and fatigue (all six fo"],"journal":["Exploration of targeted anti-tumor therapy"],"pagination":["508-521"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11222716"],"repository":["biostudies-literature"],"pubmed_title":["Chemotherapy related changes in cfDNA levels in squamous non-small cell lung cancer: correlation with symptom scores and radiological responses."],"pmcid":["PMC11222716"],"pubmed_authors":["Bal A","Prasad KT","Singh N","Garg M","Kapoor R","Ravi N","Gupta P"],"additional_accession":[]},"is_claimable":false,"name":"Chemotherapy related changes in cfDNA levels in squamous non-small cell lung cancer: correlation with symptom scores and radiological responses.","description":"<h4>Aim</h4>There is limited data on prognostic value of baseline plasma cell free DNA (cfDNA) in advanced squamous non-small cell lung cancer (sq-NSCLC). This prospective observational study aimed to assess change in plasma cfDNA levels in locally-advanced/metastatic sq-NSCLC with chemotherapy and its correlation with symptom-scores and radiological-responses.<h4>Methods</h4>Chemotherapy-naive patients with stages-IIIB/IIIC/IV sq-NSCLC (<i>n</i> = 59), smokers with chronic obstructive pulmonary disease [COPD, COPD-controls (CC); <i>n</i> = 27] and healthy-controls (<i>n</i> = 25) were enrolled. Respiratory symptom burden (RSB) and total symptom burden (TSB) were calculated from mean visual-analog-scores (VAS) of dyspnoea, cough, chest pain, hemoptysis RSB, anorexia and fatigue (all six fo","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024","modification":"2025-04-04T19:23:06.268Z","creation":"2025-04-04T19:23:06.268Z"},"accession":"S-EPMC11222716","cross_references":{"pubmed":["38966173"],"doi":["10.37349/etat.2024.00232"]}}